GZ4
Auna S.A., a healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia. The company provides prepaid healthcare plans; and dental and vision insurance plans. It also sells medicines. The company was founded in 1989 and is based in Luxembourg, Luxembourg.
GZ4 (GZ4) - Net Assets
Latest net assets as of June 2025: €1.80 Billion EUR
Based on the latest financial reports, GZ4 (GZ4) has net assets worth €1.80 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€7.17 Billion) and total liabilities (€5.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.80 Billion |
| % of Total Assets | 25.06% |
| Annual Growth Rate | 43.78% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 86.63 |
GZ4 - Net Assets Trend (2021–2024)
This chart illustrates how GZ4's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GZ4 (2021–2024)
The table below shows the annual net assets of GZ4 from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.62 Billion | -8.65% |
| 2023-12-31 | €1.78 Billion | +14.02% |
| 2022-12-31 | €1.56 Billion | +185.41% |
| 2021-12-31 | €545.91 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to GZ4's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22804300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.75 Billion | 118.52% |
| Total Equity | €1.48 Billion | 100.00% |
GZ4 Competitors by Market Cap
The table below lists competitors of GZ4 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Unicycive Therapeutics Inc
NASDAQ:UNCY
|
$116.32 Million |
|
CTT Systems AB
ST:CTT
|
$116.33 Million |
|
Kuo Yang Construction Co Ltd
TW:2505
|
$116.40 Million |
|
China Evergrande Group
F:EV1
|
$116.41 Million |
|
Qinghai Spring Medicinal Resources Technology Co Ltd
SHG:600381
|
$116.31 Million |
|
Forest Packaging Group Co Ltd
SHG:605500
|
$116.30 Million |
|
MK Electron Co. Ltd
KQ:033160
|
$116.29 Million |
|
Qijing Machinery
SHG:603677
|
$116.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GZ4's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,465,285,000 to 1,477,216,000, a change of 11,931,000 (0.8%).
- Net income of 110,271,000 contributed positively to equity growth.
- Dividend payments of 1,150,000 reduced retained earnings.
- New share issuances of 1,267,794,000 increased equity.
- Other factors decreased equity by 1,364,984,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €110.27 Million | +7.46% |
| Dividends Paid | €1.15 Million | -0.08% |
| Share Issuances | €1.27 Billion | +85.82% |
| Other Changes | €-1.36 Billion | -92.4% |
| Total Change | €- | 0.81% |
Book Value vs Market Value Analysis
This analysis compares GZ4's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.24x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.71x to 0.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €6.71 | €4.76 | x |
| 2022-12-31 | €14.41 | €4.76 | x |
| 2023-12-31 | €19.82 | €4.76 | x |
| 2024-12-31 | €19.97 | €4.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GZ4 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.46%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.51%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 4.79x
- Recent ROE (7.46%) is above the historical average (-5.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -5.34% | -1.38% | 0.68x | 5.69x | €-76.05 Million |
| 2022 | -8.04% | -3.49% | 0.37x | 6.19x | €-192.10 Million |
| 2023 | -17.33% | -6.55% | 0.50x | 5.25x | €-400.45 Million |
| 2024 | 7.46% | 2.51% | 0.62x | 4.79x | €-37.45 Million |
Industry Comparison
This section compares GZ4's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $1,653,263,054
- Average return on equity (ROE) among peers: 9.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GZ4 (GZ4) | €1.80 Billion | -5.34% | 2.99x | $116.32 Million |
| Raffles Medical Group Ltd (02M1) | $1.04 Billion | 8.64% | 0.46x | $548.22 Million |
| China Resources Medical Holdings Company Limited (1PH) | $6.14 Billion | 6.37% | 0.28x | $264.86 Million |
| Apollo Medical Holdings Inc (3AM) | $510.64 Million | 13.50% | 0.70x | $820.67 Million |
| NUVERRA ENVIR SOL (3H5) | $548.43 Million | -8.67% | 2.25x | $95.85 Million |
| Wenzhou Kangning Hospital Co. Ltd (4WK) | $1.04 Billion | 6.61% | 0.54x | $9.60 Million |
| Medicover AB (5M0B) | $562.10 Million | 18.11% | 2.00x | $967.15 Million |
| Ambea AB (publ) (6MA) | $4.68 Billion | 7.82% | 2.82x | $937.47 Million |
| Eifelhöhen-Klinik AG (EIF) | $18.66 Million | 24.17% | 2.10x | $4.38 Million |
| Garofalo Health Care S.p.A (GHC) | $333.14 Million | 6.51% | 1.55x | $126.70 Million |